Can a natural hormone curb heavy drinking? new trial aims to find out

NCT ID NCT05781009

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether the hormone pregnenolone can help people with alcohol use disorder drink less heavily. 150 adults aged 18-70 will take either 300 mg of pregnenolone or a placebo daily for 12 weeks. The main goal is to see if more people in the pregnenolone group have no heavy drinking days compared to the placebo group, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pregnenolone (300 mg daily)
What this could lead to: If successful, this could provide a new medication option to help people with alcohol use disorder reduce heavy drinking days.
What could go wrong: This is a Phase 2 trial with only 150 participants, so results may not confirm effectiveness. Pregnenolone may cause side effects or not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER

Contacts and locations

Locations

The Yale Stress Center: Yale University
RECRUITING

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.